Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVAL Study of VB-111 + paclitaxel in platinum-resistant ovarian cancer
jRCT2033210278Phase 3Recruiting
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Jun 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing VB-111 + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
ofranergene obadenovec
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2033210278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210278.